[Skip to Navigation]
December 1958

Experience with Amphotericin B for the Treatment of Systemic Mycoses

Author Affiliations

New Orleans

From the Department of Medicine of Louisiana State University Medical School and the Lung Station of Charity Hospital.

AMA Arch Intern Med. 1958;102(6):960-976. doi:10.1001/archinte.1958.00260230106014

Amphotericin B is an antibiotic produced by a species of Streptomyces. It appears to have no important antibacterial properties, but possesses highly significant activity against those yeast-like fungi which produce deep mycotic infection in man. Table 1 contains the in vitro sensitivities of the major producers of deep mycotic infection in man as determined by various investigators.1-3 Our own findings, on Sabouraud's dextrose agar at pH 7, are indicated in the Table.

Studies in experimental animals2,3 have indicated a good correlation between in vivo effectiveness and in vitro sensitivity to amphotericin B. Animal toxicity studies carried out by the Squibb Institute for Medical Research indicated that amphotericin B had a therapeutic index sufficient to justify clinical trial in human mycotic infections. Several reports 4-6 of its use in histoplasmosis and cryptococcosis have already appeared in the American literature.

Routes of Administration and Toxicity  The insolubility of crystalline or

Add or change institution